retatrutide phase 2 nejm 2023 obesity trial results

retatrutide phase 2 nejm 2023 obesity trial results Michael Weintraub, MD on X: "Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released demonstrating 25% weight loss in half of people with #obesity. This amount of weight Eli Lilly's retatrutide shows promising

Name: retatrutide phase 2 nejm 2023 obesity trial results Michael Weintraub, MD on X: "Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released demonstrating 25% weight loss in half of people with #obesity. This amount of weight Eli Lilly's retatrutide shows promising
Brand: museeartisanaletruralclion.fr
SKU: 63637938830
Price: 28.79 USD
Availability: InStock
Rating: 4.667800000000001 (8 reviews)

SKU: 63637938830

4.7

USD28.79 USD76.79

Pay in 4 interest-free payments of $7.20 Learn more

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Aug 25 - Aug 30

Description

For male patients, limited data suggest potential improvements in testosterone levels in men with obesity and hypogonadism, likely secondary to weight loss and reduced aromatase activity in adipose tissue